Platelet-derived extracellular vesicles in Huntington’s disease
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
The production and release of extracellular vesicles (EV) is a property shared by all eukaryotic cells and a phenomenon frequently exacerbated in pathological conditions. The protein cargo of EV, their cell type signature and availability in bodily fluids make them particularly appealing as biomarkers. We recently demonstrated that platelets, among all types of blood cells, contain the highest concentrations of the mutant huntingtin protein (mHtt)-the genetic product of Huntington's disease (HD), a neurodegenerative disorder which manifests in adulthood with a complex combination of motor, cognitive and psychiatric deficits. Herein, we used a cohort of 59 HD patients at all stages of the disease, including individuals in pre-manifest stages, and 54 healthy age- and sex-matched controls, to evaluate the potential of EV derived from platelets as a biomarker. We found that platelets of pre-manifest and manifest HD patients do not release more EV even if they are activated. Importantly, mHtt was not found within EV derived from platelets, despite them containing high levels of this protein. Correlation analyses also failed to reveal an association between the number of platelet-derived EV and the age of the patients, the number of CAG repeats, the Unified Huntington Disease Rating Scale total motor score, the Total Functional Capacity score or the Burden of Disease score. Our data would, therefore, suggest that EV derived from platelets with HD is not a valuable biomarker in HD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, platelet-derived EVs from both pre-manifest and manifest HD patients were shown to carry mutant huntingtin protein; however, EV release levels did not significantly differ from controls, limiting their present diagnostic utility [258].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [258]
Citations
Cites
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“What is particularly appealing about EV is that they are shed from all eukaryotic cell types [61], a phenomenon that is exacerbated in pathological conditions [62, 63].”
BackgroundExtracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Lötvall, J., Hill, A. F., Hochberg, F., Buzás, E. I., Di Vizio, D., Gardiner, C., Gho, Y. S., Kurochkin, I. V., Mathivanan, S., Quesenberry, P., et al. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.26913 · Cited by 2,451 · cited 2×
“We confirmed the presence and origin of EV derived from activated platelets by immunoblot and that EV preparations contained proteins reportedly present in platelet-derived EV [60, 66, 67] such as the platelet-surface protein CD41a, the cytoskeleton protein actin, the EV proteins TSG101 and ALIX, and the mitochondrial…”
BackgroundMembrane vesicles, current state-of-the-art: emerging role of extracellular vesicles
György, B., Szabó, T. G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., László, V., Pállinger, É., Pap, E., Kittel, Á., et al. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0689-3 · Cited by 2,074
Oxidative Stress in Neurodegenerative Diseases
Simonian, N. A., & Coyle, J. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.000503 · Cited by 1,377
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Boudreau, L. H., Duchez, A.-C., Cloutier, N., Soulet, D., Martin, N., Bollinger, J., Paré, A., Rousseau, M., Naika, G. S., Lévesque, T., et al. (2014) · Blood · doi:10.1182/blood-2014-05-573543 · Cited by 703 · cited 1×
“We confirmed the presence and origin of EV derived from activated platelets by immunoblot and that EV preparations contained proteins reportedly present in platelet-derived EV [60, 66, 67] such as the platelet-surface protein CD41a, the cytoskeleton protein actin, the EV proteins TSG101 and ALIX, and the mitochondrial…”
BackgroundBjörkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650 · cited 1×
“In one such disorder, Huntington’s disease (HD), this search has included cerebrospinal fluid (CSF) and blood sampling targeting neurotransmitters such as GABA [1, 2], as well as inflammatory markers such as clusterin [3], interleukins 6 and 8 [4] and microglial activation [5, 6].”
BackgroundGenome-wide expression profiling of human blood reveals biomarkers for Huntington's disease
Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas, H. D., Hersch, S. M., Hogarth, P., Bouzou, B., Jensen, R. V., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504921102 · Cited by 414
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364 · cited 1×
“1 3 the concentrations of neurofilament light chain [52, 53] and mutant huntingtin (mHtt)—the genetic product of HD—and their correlations with disease course [18, 54, 55].”
Background
Research works printed but not linked: 2
- Olsson MG, Davidsson S, Muhammad ZD et al (2012) Increased levels of hemoglobin and alpha1-microglobulin in Huntington’s disease. Front Biosci (Elite Ed) 4:950–957
- Lamontagne-Proulx J, St-Amour I, Labib R et al (2018) Erythrocyte-derived extracellular vesicles: a novel, robust and specific biomarker that maps to Parkinson’s disease stages. Neuro Dis (Under review)
Cited by
Role of Exosomes in Central Nervous System Diseases
Liu, W., Bai, X., Zhang, A., Huang, J., Xu, S., & Zhang, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00240 · Cited by 221
Rastogi, S., Sharma, V., Bharti, P. S., Rani, K., Modi, G. P., Nikolajeff, F., & Kumar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010440 · Cited by 174
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases
Xia, X., Wang, Y., & Zheng, J. C. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00330-0 · Cited by 92
Emerging Roles of Exosomes in Huntington’s Disease
Ananbeh, H., Vodicka, P., & Kupcova Skalnikova, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084085 · Cited by 82
Exosomes: Innocent Bystanders or Critical Culprits in Neurodegenerative Diseases
Beatriz, M., Vilaça, R., & Lopes, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.635104 · Cited by 64
“The acknowledgment that mHTT is present in exosomes was shown when murine embryonic fibroblasts (MEFs) overexpressing the exon 1 of the Htt gene showed constitutive interaction of mHTT with exosome structural proteins Alix and TSG101 mediated by Transglutaminase 2 (Diaz-Hidalgo et al., 2016).”
Background
Metadata
- Authors
- Denis, H. L., Lamontagne-Proulx, J., St-Amour, I., Mason, S. L., Weiss, A., Chouinard, S., Barker, R. A., Boilard, E., & Cicchetti, F.
- Affiliations
- University of Cambridge (GB)
- Evotec (Germany) (DE)
- Hôpital Notre-Dame (CA)
- Université Laval (CA)
- Corresponding author
- Cicchetti, Francesca
- Venue
- Journal of Neurology
- Published
- 2018-09-12
- Volume
- 265
- Issue
- 11
- Pages
- 2704-2712
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2891374052
- Cited by
- 32
- References
- 69
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 5 · 2019: 2 · 2018: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Merck Sharpe & Dohme
- Fonds de Recherche du Québec en santé
- CIHR-Huntington Society of Canada postdoctoral fellowship
- National Institute for Health Research award
- Canadian Institutes of Health Research
- Canadian Consortium on Neurodegeneration in Aging
- Desjardins scholarship from the Fondation du CHU de Québec
- Excellence scholarship from the Centre Thématique de Recherche en Neurosciences (CTRN) du CHU de Québec.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- Huntington's disease, platelet-derived extracellular vesicles, biomarkers, mutant huntingtin, platelet activation, premanifest Huntington's disease, CAG repeat expansion, disease severity
- MeSH terms
- Extracellular Vesicles, Huntingtin Protein, Adult, Aged, Blood Platelets, Female, Humans, Huntington Disease, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet-derived extracellular vesicles in Huntington’s disease. https://app.cochat.ai/papers/10.1007/s00415-018-9022-5
- The paper
- Denis, H. L., Lamontagne-Proulx, J., St-Amour, I., Mason, S. L., Weiss, A., Chouinard, S., Barker, R. A., Boilard, E., & Cicchetti, F. (2018). Platelet-derived extracellular vesicles in Huntington’s disease. Journal of Neurology. https://doi.org/10.1007/s00415-018-9022-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.